Would a CYP2B6 test help HIV patients being treated with efavirenz?

被引：3

作者：

Sukasem, Chonlaphat ^{[1
]}

Sungkanuparph, Somnuek ^{[2
]}

机构：

[1] Mahidol Univ, Ramathibodi Hosp, Div Pharmacogen & Personalized Med, Bangkok 10400, Thailand

[2] Mahidol Univ, Ramathibodi Hosp, Dept Med, Div Infect Dis, Bangkok 10400, Thailand

来源：

PHARMACOGENOMICS | 2013年 / 14卷 / 09期

关键词：

CYP2B6; efavirenz; HIV; pharmacogenetics; polymorphism; toxicity; PLASMA-CONCENTRATIONS; PHARMACOGENETIC MARKERS; POLYMORPHISM; IMPACT;

D O I：

10.2217/pgs.13.69

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

[No abstract available]

引用

页码：999 / 1001

页数：3

共 15 条

[1]

[Anonymous], AIDS

[2] Relationship between antiretroviral plasma concentration and emergence of HIV-1 resistance mutations at treatment failure [J].

Fabbiani, M. ;

Bracciale, L. ;

Ragazzoni, E. ;

Santangelo, R. ;

Cattani, P. ;

Di Giambenedetto, S. ;

Fadda, G. ;

Navarra, P. ;

Cauda, R. ;

De Luca, A. .

INFECTION, 2011, 39 (06) :563-569

[3] Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P4502B6*6 and*26 [J].

Gatanaga, Hiroyuki ;

Hayashida, Tsunefusa ;

Tsuchiya, Kiyoto ;

Yoshino, Munehiro ;

Kuwahara, Takeshi ;

Tsukada, Hiroki ;

Fujimoto, Katsuya ;

Sato, Isao ;

Ueda, Mikio ;

Horiba, Masahide ;

Hamaguchi, Motohiro ;

Yamamoto, Masahiro ;

Takata, Noboru ;

Kimura, Akiro ;

Koike, Takao ;

Gejyo, Fumitake ;

Matsushita, Shuzo ;

Shirasaka, Takuma ;

Kimura, Satoshi ;

Oka, Shinichi .

CLINICAL INFECTIOUS DISEASES, 2007, 45 (09) :1230-1237

[4] Presence of the CYP2B6 516G> T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients [J].

Gounden, Verena ;

van Niekerk, Chantal ;

Snyman, Tracy ;

George, Jaya A. .

AIDS RESEARCH AND THERAPY, 2010, 7

[5]

Haas DW, 2004, AIDS, V18, P2391

[6] A Systematic Review of the Psychiatric Side-Effects of Efavirenz [J].

Kenedi, Christopher A. ;

Goforth, Harold W. .

AIDS AND BEHAVIOR, 2011, 15 (08) :1803-1818

[7] CYP2B6 genotype is a strong predictor of systemic exposure to efavirenz in HIV-infected Zimbabweans [J].

Maimbo, Milimo ;

Kiyotani, Kazuma ;

Mushiroda, Taisei ;

Masimirembwa, Collen ;

Nakamura, Yusuke .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 68 (03) :267-271

[8] Impact of Pharmacogenetic Markers of CYP2B6, Clinical Factors, and Drug-Drug Interaction on Efavirenz Concentrations in HIV/Tuberculosis-Coinfected Patients [J].

Manosuthi, Weerawat ;

Sukasem, Chonlaphat ;

Lueangniyomkul, Aroon ;

Mankatitham, Wiroj ;

Thongyen, Supeda ;

Nilkamhang, Samruay ;

Manosuthi, Sukanya ;

Sungkanuparph, Somnuek .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (02) :1019-1024

[9] Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients [J].

Marzolini, C ;

Telenti, A ;

Decosterd, LA ;

Greub, G ;

Biollaz, J ;

Buclin, T .

AIDS, 2001, 15 (01) :71-75

[10]

Stähle L, 2004, THER DRUG MONIT, V26, P267, DOI 10.1097/00007691-200406000-00008

← 1 2 →